Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04637763 · ClinicalTrials.gov registry record · Phase 1
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
A Phase 1 study of Lymphoma and Non-Hodgkin Lymphoma, sponsored by Caribou Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT04637763 is a Phase 1 study of Lymphoma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Caribou Biosciences. The registered enrollment target is 72 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04637763, a Phase 1 study of Lymphoma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Caribou Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC CB-010
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- HonorHealth - Scottsdale
- University of Arizona Cancer Center - Tucson
California
- University of California San Diego Moores Cancer Center - La Jolla
- University of Southern California, Norris Comprehensive Cancer Center - Los Angeles
- Chao Family Comprehensive Cancer Center/University of California Irvine - Orange
Georgia
- Bone and Marrow Transplant Group of Georgia - Atlanta
- Georgia Cancer Center at Augusta University - Augusta
Kentucky
- University of Kentucky Markey Cancer - Lexington
- Norton Cancer Institute - Louisville
New Jersey
- Hackensack Medical Center - Hackensack
- Atlantic Health System - Morristown
New York
- Nyu Langone Health - New York
- Montefiore Medical Center - The Bronx
Alabama
- University of Alabama at Birmingham - Birmingham
Arkansas
- University of Arkansas - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2021-05-26 |
| Est. Completion | 2025-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04637763
The ClinicalTrials.gov registry entry for NCT04637763 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The listed sponsor is Caribou Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04637763 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Arizona, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT04637763 about?
NCT04637763 is a clinical study titled "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)". CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
What is the current status of trial NCT04637763?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2021-05-26. Estimated completion is 2025-09.
What conditions does trial NCT04637763 study?
This clinical trial studies the following conditions: Lymphoma, Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT04637763?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), CB-010 (GENETIC).
Who is sponsoring clinical trial NCT04637763?
This trial is sponsored by Caribou Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04637763 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.